The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of cell of origin, gene rearrangements, and frontline treatment on incidence of secondary central nervous system lymphoma in newly diagnosed diffuse large B-cell lymphoma.
 
Ayo Falade
No Relationships to Disclose
 
Raphael Mwangi
No Relationships to Disclose
 
Paul Hampel
Consulting or Advisory Role - Abbvie (Inst)
Research Funding - AstraZeneca (Inst); BeiGene (Inst)
 
Syeda Mina
No Relationships to Disclose
 
Jonas Paludo
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst)
Research Funding - Biofourmis (Inst); Karyopharm Therapeutics (Inst)
 
Saurabh Zanwar
No Relationships to Disclose
 
Eric Mou
Consulting or Advisory Role - Abbvie
 
Xavier Andrade-Gonzalez
No Relationships to Disclose
 
Gita Thanarajasingam
Consulting or Advisory Role - Novartis (Inst)
 
Anne Novak
No Relationships to Disclose
 
Yucai Wang
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Honoraria - Kite, a Gilead company (Inst)
Consulting or Advisory Role - Abbvie; AstraZeneca (Inst); BeiGene (Inst); Genmab (Inst); Incyte (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Loxo (Inst); TG Therapeutics (Inst)
Research Funding - Abbvie (Inst); BeiGene (Inst); Genentech (Inst); Genmab (Inst); Incyte (Inst); InnoCare (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); MorphoSys (Inst); Novartis (Inst)
 
Carrie Thompson
No Relationships to Disclose
 
Ivana Micallef
No Relationships to Disclose
 
Stephen Ansell
Honoraria - Answers in CME; Medscape; Research to Practice; WebMD
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Regeneron (Inst); Seagen (Inst); Step Pharma (Inst); Takeda (Inst)
 
Matthew Maurer
Employment - Exact Sciences (I)
Stock and Other Ownership Interests - Exact Sciences (I)
Consulting or Advisory Role - AstraZeneca; BMS (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Genmab (Inst); Roche/Genentech (Inst)
 
Brian Link
Consulting or Advisory Role - Genentech/Roche; MEI Pharma
Research Funding - Genentech/Abbvie (Inst); Genmab (Inst); Pharmacyclics/Janssen (Inst)
Expert Testimony - Amgen
 
James Cerhan
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene (Inst); Protagonist Therapeutics
Research Funding - Celgene (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genmab (Inst)
(OPTIONAL) Uncompensated Relationships - Regeneron (Inst)
 
Thomas Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
Research Funding - Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - BeiGene; Incyte; Loxo/Lilly; MorphoSys; Seagen; Tessa Therapeutics
 
Jose Villasboas
Consulting or Advisory Role - Curio Science (Inst); Kite/Gilead (Inst); Regeneron (Inst); TG Therapeutics (Inst)
Research Funding - Aptose Biosciences (Inst); Celgene/Bristol-Myers Squibb (Inst); Enterome (Inst); Epizyme (Inst); Genentech/Roche (Inst); Regeneron (Inst)
 
Jithma Abeykoon
No Relationships to Disclose